At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 14 enrolled
Drug / intervention
Amrubicin +4 moredrug
Likely dose
Amrubicin 80 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Study of Amrubicin in Combination With Lenalidomide and Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma
In Brief
A Phase 2 clinical trial evaluating Amrubicin, Lenalidomide, and 3 other interventions for Multiple Myeloma. Completed, enrolled 14 participants across 1 site.
Detailed Summary
To assess if amrubicin is safe and useful for patients with multiple myeloma requiring additional treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesUnited States
CollaboratorsCelgene Corporation
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMay 2011
Enrollment StartAug 2011
Primary CompletionJul 2016
Study CompletionJul 2017
TodayJul 2026
First PostedMay 18, 2011
Enrollment StartAug 1, 2011
Primary CompletionJul 1, 2016
Study CompletionJul 1, 2017
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 15.1 years ago
Interventions
Amrubicindrug
40, 60, or 80 mg/m2 intravenous (IV)
Lenalidomidedrug
15 mg daily by mouth
Dexamethasonedrug
40 mg weekly by mouth
Aspirindrug
81 or 325 mg daily by mouth
Pegfilgrastimdrug
6 mg subcutaneous on Day 2